Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Nexo Therapeutics has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
Nexo Therapeutics's investors include New Enterprise Associates, Cormorant Asset Management, Versant Ventures.
Nexo Therapeutics is headquartered in Littleton, United States.
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Nexo Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nexo Therapeutics — Funding & Investors." VCBacked, July 26, 2023, https://www.vcbacked.co/company/nexo-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Nexo Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/nexo-therapeutics
{{cite web |title=Nexo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nexo-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated